Subgam (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
65 | 原発性免疫不全症候群 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01884311 (ClinicalTrials.gov) | August 20, 2015 | 14/6/2013 | Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases | A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases | Primary Immune Deficiency Disorders;Common Variable Immunodeficiency;X-linked Agammaglobulinaemia;Hyperimmunoglobulin M Syndrome | Biological: Subgam | Bio Products Laboratory | NULL | Completed | 2 Years | 75 Years | All | 38 | Phase 3 | United States |